Aridis is a privately held biotechnology company focused on developing new breakthrough therapies for infectious diseases and addressing the growing problem of antibiotic resistance. Aridis has a deep, diversified portfolio of clinical and pre-clinical stage anti-infective product candidates that are complimented by a fully human monoclonal antibody discovery platform technology.
Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly alter the current trajectory of increasing antibiotic resistance and improve the health outcome of many of the most serious life-threatening infections particularly in hospital settings. In recognition of their importance, Aridis products have been funded by approximately $40 million from leading granting agencies such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health & Human Services’ BARDA, USAID, Regional Centers of Excellence, as well as the non-profit PATH/Gates Foundation.